• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc (NQ: APVO )

0.2480 -0.0220 (-8.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc

< Previous 1 2 Next >
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
October 29, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 18, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
September 16, 2024
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
September 16, 2024
Via ACCESSWIRE
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
August 13, 2024
Via ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
May 14, 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
March 05, 2024
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
September 13, 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
August 08, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
July 01, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
June 28, 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
November 14, 2023
Via ACCESSWIRE
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
August 10, 2023
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
May 11, 2023
Via ACCESSWIRE
Aptevo Participating in the BIO International Convention
June 03, 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
May 08, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
April 15, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
April 11, 2024
Via ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
April 10, 2024
Via ACCESSWIRE
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
March 30, 2023
Via ACCESSWIRE
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
March 30, 2023
Via ACCESSWIRE
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
February 13, 2023
Via ACCESSWIRE
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
March 18, 2024
Via ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
March 07, 2024
Via ACCESSWIRE
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
March 04, 2024
Via ACCESSWIRE
Aptevo to Present at Bio-Europe Conference
November 01, 2023
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
August 04, 2023
Via ACCESSWIRE
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
January 09, 2023
Via ACCESSWIRE
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
August 01, 2023
Via ACCESSWIRE
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
July 18, 2023
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap